GENMAB ASDK 1 news, videos and press releases
For more news please use our advanced search feature.
GENMAB ASDK 1 - More news...
GENMAB ASDK 1 - More news...
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
- Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
- Genmab to Present at Citi’s Global Healthcare Conference
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Financial Results for the First Nine Months of 2024
- Genmab to Present at Jefferies London Healthcare Conference
- Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
- Major Shareholder Announcement
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
- TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
- Genmab Announces Changes to its Executive Committee
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Genmab Announces Financial Results for the First Half of 2024
- Genmab Updates 2024 Financial Guidance
- Genmab Takes Full Control of Acasunlimab Development Program
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
- Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
- Completion of Share Buy-back Program
- EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Transactions in Connection with Share Buy-back Program
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
